However, several cancer-specific investigations observed an in vitro tumour microenvironment phenomenon where DC2s shifted towards a DC3 like-phenotype, acquiring CD14 and CD163 expression, in response to tumour-derived factors including IL-6 and M-CSF [118,122]. This evidence concerns the gene CD163 and neoplasm.